Actinogen Medical Ltd
Price Chart
OHLC · volume · moving averages
Market Statistics
Today's trading range
Valuation
Fundamental multiples
Trading Activity
Volume & order book
Performance
Returns across timeframes
Technical Indicators
Momentum & moving averages
— From the desk
Latest News
Actinogen Gets Third DMC Green Light for XanaMIA as November Topline Nears
Actinogen's XanaMIA gets third DMC green light; trial proceeds unchanged as November 2026 topline readout nears, easing near-term interruption risk.
Actinogen Medical’s Xanamem shows promising results in depression treatment trials
Australian biotechnology company Actinogen Medical (ASX: ACW) has received further positive analysis from studies of its Xanamem treatment for symptoms of depression. The consistent benefits observed in the XanaCIDD phase 2a depression trial data support the conclusion that a 10 milligram Xanamem dose is clinically active in controlling brain cortisol and has clinically-significant anti-depressant activity. […]
Market wrap: inflation pushes share prices lower on last trading day of the financial year
Inflation was the word on everybody’s lips as they dumped shares on the last trading day of the financial year but it was the price of goods and services rather than shares that had caught their attention. The week’s stunning news that inflation had reared back up to 4% for the year to May brought […]
Actinogen’s Xanamem could slow Alzheimer’s progress, new biomarker trial reveals
A biomarker trial of Actinogen Medical’s (ASX: ACW) lead candidate Xanamem has been published in the peer-reviewed Journal of Alzheimer’s Disease, with results showing the drug has the potential to slow disease progression in patients with elevated levels of phosphorylated tau (pTau). The trial comprised 72 participants from Actinogen’s previous XanADu Phase 2a trial who […]